BioLineRx Ltd. — Regulatory Filings 2013

Aug 6, 2013

6-K 1 zk1313468.htm 6-K zk1313468.htm Licensed to: zkglobal Document Created using EDGARizer 2020 5.4.4.0 Copyright 1995 - 2013 Thomson Reuters. All rights reserved.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2013

---

BioLineRx Ltd.

(Translation of Registrant’s name into English)

---

P.O. Box 45158

19 Hartum Street

Jerusalem 91450, Israel

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F þ Form 40-F o

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) underthe Securities Exchange Act of 1934:

Yes o No þ

On August 6, 2013, the Registrant will issue a press release announcing its financial results for the three months and six months ended June 30, 2013. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of June 30, 2013, and for the three months and six months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated August 6, 2013;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of June 30, 2013, and for the three months and six months then ended;

Exhibit 3 - Registrant’s operating and financial review as of June 30, 2013, and for the three months and six months then ended.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By:	/s/ Philip Serlin
	Philip Serlin
	Chief Financial and Operating Officer

Dated: August 6, 2013